Pharmacosmos vs. Dr. Reddy’s: ANDA Patent Battle Over Trilaciclib (COSELA®) Ends in Consolidation
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Pharmacosmos A/S et al. v. Dr. Reddy’s Laboratories, Ltd. et al. |
| Numéro de dossier | 2:25-cv-03967 (Consolidated into Lead Case 2:25-cv-3218) |
| Tribunal | Tribunal fédéral de première instance pour le district du New Jersey |
| Durée | May 7, 2025 – January 6, 2026 244 days |
| Résultat | Consolidation (No Adjudication on Merits) |
| Brevets en cause | |
| Produits incriminés | Generic version of COSELA® (trilaciclib) for injection |
Aperçu du dossier
Les parties
⚖️ Demandeur
Danish-founded specialty pharmaceutical group holding U.S. commercial rights to COSELA® (trilaciclib), the first FDA-approved myeloprotective agent.
🛡️ Défendeur
Major Indian multinational generic pharmaceutical company with an established U.S. ANDA filing history and extensive Hatch-Waxman litigation experience.
This litigation also involved parallel ANDA actions against **Teva Pharmaceuticals** and **Hetero Labs**, which were later consolidated with this case.
Les brevets en cause
Pharmacosmos asserted 13 U.S. patents covering trilaciclib’s composition, formulation, and method-of-use claims, creating a multi-layered exclusivity structure. These patents collectively protect:
- • US8598186B2 | US8598197B2 | US9487530B2 | US9957276B2
- • US10085992B2 | US10189849B2 | US10189850B2 | US10927120B2
- • US10966984B2 | US11040042B2 | US11529352B2 | US11717523B2
- • US12168666B2
Le produit incriminé
Dr. Reddy’s sought FDA approval for a generic version of COSELA® (trilaciclib) for injection, an intravenous drug product, triggering Pharmacosmos’s Hatch-Waxman infringement action based on Dr. Reddy’s Paragraph IV certifications against the listed patents.
Représentation juridique
Pharmacosmos was represented by **Gibbons PC**, with attorneys Abigail Struthers, Christine A. Gaddis, Daniel L. Reisner, David DeNuyl, David E. DeLorenzI, Jeremy Cobb, and Jerrit Yang.
Dr. Reddy’s was represented by **Midlige Richter LLC**, with attorneys Anna Sonju, Ivan M. Poullaos, James S. Richter, Jovial Wong, and Sharon Lin.
Developing a generic or a new branded drug?
Check for potential patent roadblocks with our AI-powered FTO analysis tools.
Chronologie du litige et historique de la procédure
| étape importante | Date |
| Plainte déposée | 7 mai 2025 |
| Case Closed (Consolidation Order) | 6 janvier 2026 |
| Durée totale | 244 jours |
The case was filed in the U.S. District Court for the District of New Jersey — a highly strategic choice. New Jersey’s district court is among the most experienced venues for Hatch-Waxman ANDA litigation in the United States, given its geographic proximity to major pharmaceutical industry headquarters and its judges’ deep familiarity with complex pharmaceutical patent disputes.
Within the case’s 244-day lifespan, the most consequential procedural development was consolidation with two parallel matters: Pharmacosmos v. Teva Pharmaceuticals (No. 2:25-cv-3218) and Pharmacosmos v. Hetero Labs (No. 2:25-cv-3945). The stipulated consolidation order, entered pursuant to Federal Rule of Civil Procedure 42, merged all three actions for pretrial purposes under lead docket No. 25-3218, preserving each party’s right to request separate trials under Rule 42(b).
The 244-day period from filing to administrative closure reflects the procedural efficiency of consolidation rather than a substantive resolution on the merits at this stage.
Le verdict et l'analyse juridique
Résultat
Case No. 2:25-cv-03967 was closed administratively following the court-approved stipulated consolidation of three related Hatch-Waxman infringement actions. No damages were awarded, no injunction was issued, and no merits determination was reached within this specific docket. Substantive litigation — including claim construction, validity challenges, and infringement analyses — continues under the consolidated lead case No. 2:25-cv-3218.
The basis of termination reflects procedural consolidation, not settlement, dismissal, or adjudication on the merits.
Analyse des causes du verdict
The infringement action arises under the Hatch-Waxman Act framework, wherein a generic applicant’s Paragraph IV ANDA filing constitutes a technical act of infringement sufficient to trigger a 30-month stay of FDA approval upon timely suit. Pharmacosmos’s assertion of 13 patents against three simultaneous generic challengers suggests coordinated ANDA filings by Dr. Reddy’s, Teva, and Hetero — a pattern increasingly common when generics anticipate strong branded market exclusivity and seek to neutralize it collectively.
The decision to consolidate all three actions for pretrial purposes reflects both judicial economy principles and the practical reality that the same patents, claim constructions, and validity arguments will apply across all defendants. Coordinated Markman hearings, expert schedules, and discovery protocols will benefit all parties.
Signification juridique
The consolidation framework established here has significant implications:
- • Claim Construction: A single Markman hearing will govern claim interpretation for all 13 patents across all three defendants — meaning any adverse construction could simultaneously weaken Pharmacosmos’s position against Teva and Hetero, not just Dr. Reddy’s.
- • Validity Challenges: With three well-resourced generic defendants pooling invalidity arguments, inter partes review (IPR) petitions at the USPTO become a heightened risk. Patent practitioners should monitor USPTO filings against the 13 asserted patents closely.
- • Patent Portfolio Depth: Pharmacosmos’s assertion of patents spanning application numbers from US13/869520 (2013 filing vintage) through US17/236687 (a more recent application) demonstrates a prosecution strategy designed to maintain overlapping exclusivity periods — a model for other pharmaceutical patent holders protecting complex small-molecule injectables.
Analyse de la liberté d'exploitation (FTO)
Ce cas met en évidence les risques critiques liés à la propriété intellectuelle dans le développement de produits pharmaceutiques. Choisissez la prochaine étape :
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View all 13 asserted patents and their families
- See which companies are most active in trilaciclib IP
- Understand common claim construction patterns in ANDA cases
🔍 Vérifier les risques liés à mon produit
Run a comprehensive FTO analysis for your own generic or branded technology.
- Saisissez la description de votre médicament ou ses caractéristiques techniques
- L'IA identifie les brevets pharmaceutiques susceptibles de constituer un obstacle
- Get actionable risk assessment report for your ANDA filing
Zone à haut risque
Trilaciclib composition & formulation
13 Patents Asserted
Covering composition, formulation, method-of-use
Coordinated Generic Challenge
Multiple defendants benefit from consolidation
✅ Points clés à retenir
Multi-defendant ANDA consolidation under Rule 42 is increasingly utilized in D.N.J. pharmaceutical patent cases — prepare unified Markman strategies.
Rechercher la jurisprudence connexe →Pharmacosmos’s 13-patent assertion represents a robust pharmaceutical patent thicket model worth studying for portfolio design.
Explorer les portefeuilles de brevets →IPR petition risk is amplified when multiple well-resourced generic defendants coordinate invalidity strategies.
Monitor PTAB filings →Pharmaceutical patent lifecycle management must account for simultaneous multi-generic challenges — build consolidation scenarios into litigation budgets.
Accéder à l'analyse des litiges →FTO clearance for ANDA products should extend beyond composition patents to formulation and method-of-use patent families.
Lancer l'analyse FTO →Foire aux questions
Pharmacosmos asserted 13 U.S. patents including US8598186B2, US8598197B2, US9487530B2, US10189849B2, US10966984B2, US11717523B2, US12168666B2, and six additional patents covering trilaciclib composition, formulation, and method-of-use claims.
The case was closed administratively following court-approved consolidation with two related Hatch-Waxman actions against Teva and Hetero Labs into lead case No. 2:25-cv-3218, pursuant to Federal Rule of Civil Procedure 42. Substantive litigation continues under the consolidated docket.
A single Markman claim construction ruling will apply to all three defendants simultaneously, meaning adverse constructions could benefit all generic challengers collectively — increasing pressure on Pharmacosmos to secure broad, defensible claim interpretations early in proceedings.
Prêt à renforcer votre stratégie en matière de brevets pharmaceutiques ?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision for ANDA filings and drug development.
Références
- PACER — D.N.J. Case No. 2:25-cv-03967 (and 2:25-cv-3218)
- U.S. Patent and Trademark Office (USPTO)
- Google Patents — US10927120B2 (Example)
- U.S. Food and Drug Administration (FDA) — Paragraph IV Certifications Database
- Cornell Legal Information Institute — Federal Rules of Civil Procedure Rule 42
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.